Ianacone David C, Smith Alden F, Casselbrant Margaretha L, Ensink Robbert J H, Buchinsky Farrel, Melaku Abebe, Isaacson Glenn
Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
Children's Hospital of Pittsburgh, PA, USA; Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Int J Pediatr Otorhinolaryngol. 2017 Dec;103:133-136. doi: 10.1016/j.ijporl.2017.10.024. Epub 2017 Oct 19.
To determine the prevalence of chronic ear disease in HIV+, highly active anti-retroviral therapy (HAART)-treated children and compare this to the prevalence in healthy children of similar age living in a similar setting.
From previous clinical work in Ethiopia, we suspected that chronic middle ear disease was common both in the general pediatric population and especially among children with HIV/AIDS. Few studies have examined the prevalence of chronic ear disease in HIV + children, particularly in those treated with HAART.
Full examination of the head and neck was performed by otolaryngologists. This including cleaning of cerumen, otoscopy and microscopic otoscopy when needed. Patient's medical records were reviewed. Presence or absence of tympanic membrane (TM) perforation (unilateral or bilateral), tympanosclerosis, TM atrophy, otorrhea and/or cholesteatoma was documented.
112 HIV+ and 162 healthy (HIVU) children were included. Prevalence of TM perforations was 17% in the HIV + infected versus 3% in the HIVU (Fisher's-Exact-Test; OR: 7.2, 95% CI 2.5-20, p-value <0.0001). Presence of unilateral TM perforations was 12% in the HIV + population and 2% in the HIVU population (Fisher's-Exact-Test; OR: 6.8, 95% CI 2.0-22, p-value 0.002). The presence of bilateral perforations was 4% in the HIV + population and 1% in the HIVU population (Fisher's-Exact-Test; OR: 6.8, 95% CI 1.1-42, p-value 0.088). In the HIV + cohort, 2% were diagnosed with cholesteatoma compared to 0% in the HIVU population (95% CI HIV+ 0.002-0.06; HIVU 0.0-0.02) and 8% of HIV + subjects had active middle ear discharge, compared to 0% in the HIVU population (95% CI HIV+ 0.04-0.1; HIVU 0.0-0.02). Neither tympanosclerosis nor tympanic membrane atrophy was more frequent in the HIV + population compared to the HIVU population. Persistent or recurrent TM perforation was not more frequent in children with prior tympanoplasty in the HIV + population compared to the HIVU population.
TM perforations are significantly more common in HAART-treated HIV + children than in healthy, age-matched HIVU population. Otorrhea and cholesteatoma were found only in the HIV + cohort.
确定接受高效抗逆转录病毒治疗(HAART)的HIV阳性儿童慢性耳部疾病的患病率,并与生活在类似环境中的同龄健康儿童的患病率进行比较。
根据此前在埃塞俄比亚开展的临床工作,我们怀疑慢性中耳疾病在普通儿科人群中很常见,尤其是在感染艾滋病毒/艾滋病的儿童中。很少有研究调查HIV阳性儿童,特别是接受HAART治疗的儿童慢性耳部疾病的患病率。
由耳鼻喉科医生对头颈部进行全面检查。这包括必要时清理耵聍、耳镜检查和显微镜耳镜检查。查阅患者的病历。记录鼓膜(TM)穿孔(单侧或双侧)、鼓室硬化、TM萎缩、耳漏和/或胆脂瘤的有无。
纳入了112名HIV阳性儿童和162名健康(未感染HIV)儿童。HIV阳性感染者中TM穿孔的患病率为17%,而未感染HIV者为3%(Fisher精确检验;比值比:7.2,95%置信区间2.5 - 20,p值<0.0001)。HIV阳性人群中单侧TM穿孔的发生率为12%,未感染HIV人群中为2%(Fisher精确检验;比值比:6.8,95%置信区间2.0 - 22,p值0.002)。HIV阳性人群中双侧穿孔的发生率为4%,未感染HIV人群中为1%(Fisher精确检验;比值比:6.8,95%置信区间1.1 - 42,p值0.088)。在HIV阳性队列中,2%被诊断为胆脂瘤,而未感染HIV人群中为0%(95%置信区间:HIV阳性0.002 - 0.06;未感染HIV 0.0 - 0.02),8%的HIV阳性受试者有中耳活动性分泌物,而未感染HIV人群中为0%(95%置信区间:HIV阳性0.04 - 0.1;未感染HIV 0.0 - 0.02)。与未感染HIV人群相比,HIV阳性人群中鼓室硬化和鼓膜萎缩并不更常见。与未感染HIV人群相比,HIV阳性人群中既往有鼓膜成形术的儿童持续性或复发性TM穿孔并不更常见。
接受HAART治疗的HIV阳性儿童中TM穿孔明显比健康的、年龄匹配的未感染HIV人群更常见。耳漏和胆脂瘤仅在HIV阳性队列中发现。